281 related articles for article (PubMed ID: 24522938)
1. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
2. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Damian DL; Shannon KF; Saw RP; Thompson JF
Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
[TBL] [Abstract][Full Text] [Related]
3. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
4. Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
Veverka KK; Jakub JW; Baum CL
Dermatol Surg; 2018 Dec; 44(12):1501-1508. PubMed ID: 29985863
[TBL] [Abstract][Full Text] [Related]
5. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
Damian DL; Thompson JF
J Am Acad Dermatol; 2007 May; 56(5):869-71. PubMed ID: 17276544
[TBL] [Abstract][Full Text] [Related]
6. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg.
Damian DL; Thompson JF
Am J Clin Dermatol; 2011 Dec; 12(6):403-4. PubMed ID: 21967115
[No Abstract] [Full Text] [Related]
7. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.
Gibbons IL; Sonagli M; Bertolli E; Macedo MP; Pinto CAL; Duprat Neto JP
An Bras Dermatol; 2018 Mar; 93(2):299-301. PubMed ID: 29723355
[TBL] [Abstract][Full Text] [Related]
8. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone.
Martiniuk F; Damian DL; Thompson JF; Scolyer RA; Tchou-Wong KM; Levis WR
J Drugs Dermatol; 2010 Nov; 9(11):1368-72. PubMed ID: 21061759
[TBL] [Abstract][Full Text] [Related]
9. Alopecia areata: topical immunotherapy treatment with diphencyprone.
Avgerinou G; Gregoriou S; Rigopoulos D; Stratigos A; Kalogeromitros D; Katsambas A
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):320-3. PubMed ID: 18005118
[TBL] [Abstract][Full Text] [Related]
10. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1979 Mar; 91(5):150-4. PubMed ID: 425533
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of alopecia areata with diphencyprone].
Suditu G; Toma A; Voiculescu M
Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):760-2. PubMed ID: 12092234
[TBL] [Abstract][Full Text] [Related]
12. Level of contact hypersensitivity response to diphencyprone and keratinocyte cancer.
Bullen A; Polcz M; Rowe CJ; Byrom L; Soyer HP; Khosrotehrani K
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):2101-2105. PubMed ID: 31265155
[TBL] [Abstract][Full Text] [Related]
13. Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion.
Lo MC; Garioch J; Moncrieff MD
J Plast Reconstr Aesthet Surg; 2020 Jul; 73(7):1263-1267. PubMed ID: 32245735
[TBL] [Abstract][Full Text] [Related]
14. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
Fujimura T; Furudate S; Kakizaki A; Kambayashi Y; Haga T; Hashimoto A; Aiba S
J Dermatol; 2016 Jun; 43(6):686-9. PubMed ID: 26663262
[TBL] [Abstract][Full Text] [Related]
15. Local and intralesional therapy of in-transit melanoma metastases.
Testori A; Faries MB; Thompson JF; Pennacchioli E; Deroose JP; van Geel AN; Verhoef C; Verrecchia F; Soteldo J
J Surg Oncol; 2011 Sep; 104(4):391-6. PubMed ID: 21858834
[TBL] [Abstract][Full Text] [Related]
16. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone.
Hinz T; Ehler LK; Bieber T; Schmid-Wendtner MH
Eur J Dermatol; 2013; 23(4):532-3. PubMed ID: 24002471
[No Abstract] [Full Text] [Related]
17. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
18. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
19. Response rates of cutaneous melanoma metastases to diphencyprone: A meta-analysis.
Lôbo MM; Calsavara VF; Ricci BV; Lopes Pinto CA; Bertolli E; Duprat Neto JP
J Am Acad Dermatol; 2020 Dec; 83(6):1812-1813. PubMed ID: 32289400
[No Abstract] [Full Text] [Related]
20. Re-inventing intratumoral immunotherapy for melanoma.
Triozzi PL; Tuthill RJ; Borden E
Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
